Group items tagged

Small but significant breakthrough studies on people who have been able to overcome or control HIV were presented at a major world conference on ways to stem the three-decade-old disease. One study focused on a group of 12 patients in France who began treatment on antiretroviral drugs within 10 weeks of becoming infected with human immunodeficiency virus, but then stopped the therapy after nearly three years.

PBR Staff Writer Published 25 February 2014 Bristol-Myers Squibb (BMS) has received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for its investigational DCV Dual Regimen (daclatasvir and asunaprevir) for use as a combination therapy in the treatment of genotype 1b chronic hepatitis C infection (HCV).

Venus Factor a breakthrough that actually makes losing weight easier for women.Weight Loss Program For Women ONLY

One of the long-standing medical mysteries is the diagnosis of diabetes in majority of patients suffering from high blood pressure. The reason for this had been unknown. But now, an international team of universities have made a breakthrough. The research, published online in 'Circulation Research', involved contributions from collaborating scientists in Brazil, Germany, Lithuania, and Serbia, as well as the UK and New Zealand. The important new discovery has shown that a small protein cell glucagon-like peptide-1 (GLP-1) couples the body's control of blood sugar and blood pressure. Professor Julian Paton, a senior author, and director of Manaaki Manawa, The Centre for Heart Research at the University of Auckland, said: "We've known for a long time that hypertension and diabetes are inextricably linked and have finally discovered the reason, which will now inform new treatment strategies." GLP-1 is released from the wall of the gut after eating and acts to stimulate insulin from the pancreas to control blood sugar levels. This was known but what has now been unearthed is that GLP-1 also stimulates a small sensory organ called the carotid body located in the neck.

In our quest for perfect skin, the landscape of dermatology and skin care has evolved dramatically, offering breakthrough treatments and solutions. The pursuit of a blemish-free, radiant complexion is no longer a distant dream, thanks to advancements in medical aesthetics and skincare technology. From non-invasive procedures to tailor-made skincare regimens, individuals now have access to a plethora of options designed to target specific skin concerns. This article explores the cutting-edge treatments that promise to diminish imperfections and reveal flawless skin, transforming not just how we look but also how we feel about ourselves. Botox Injections Botox, or Botulinum toxin, has gained immense popularity for its ability to smooth out wrinkles and fine lines. It works by temporarily paralyzing the facial muscles responsible for creating these imperfections. The procedure involves injecting small amounts of the neurotoxin into targeted areas, such as the forehead, crow's feet, and frown lines between the brows. The effects of Botox typically last for three to four months, making it a popular choice for those seeking quick and noticeable results. The people at sdbotox.com note that it is also a popular preventative treatment for those looking to delay the formation of wrinkles. With consistent use, Botox can actually prevent fine lines and wrinkles from appearing in the first place, making it an attractive option for individuals in their late 20s and early 30s.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Please Note: The material on this site is provided for informational purposes only and is not medical advice. Always consult your physician before beginning any diet or exercise program.

Maybe it's already been answered below: What is Customized Fat Loss? There is nothing like the CFL anywhere. Period CFL is a professional, truly customized approach to nutrition. CFL is breakthrough nutritional software that when combined with exercise, torches fat in record time while preserving your lean muscle. It is designed to explode you through your fat loss plateau and have you turning heads 365 days a year!

We are not trying to create any hoax, nor do we intend to create any hype for no reason! A report by Australia's Breakthrough National Centre for Climate Restoration (BNCCR) claims that we have just another 31 years after which the climate change will cause more than 90 percent of humans to wipe out. So, if we do not mend our ways in harming the climate, by 2050, the human race will cease to exist!

The number of people suffering from addiction is at an all time high, with more people seeking treatment across the USA due to the fentanyl crisis, but new studies have shown that addiction drugs may not only be able to aid those suffering from the deadly disease, but also aid people suffering from long COVID. While there has long been research underway to find a cure for the likes of alcoholism and drug addiction, it turns out naltrexone, a drug used in the addiction treatment space, is helping people who have been suffering from headaches, seizures and fatigue as a result of long COVID. According to Dr. Paul Valbuena at The River Source, an Arizona drug rehab, naltrexone is typically used by rehab centers and prescribed to patients suffering from addiction to reduce cravings and the feeling of euphoria associated with substance use disorder, giving patients clarity and focus to concentrate on recovery. Thanks to a recent report, that has also been revealed to be the case for those suffering with long COVID too, with Lauren Nichols, a long COVID sufferer from Chicago being prescribed the drug by her doctor. She found that the drug helped quell her seizures and headaches, alowing her to think clearly and get on with her life as normal. It's been a similar story for other patients too, and has marked a major breakthrough in the bid to help those who are still suffering in the aftermath of the pandemic.

The first big breakthrough in 30 years of Alzheimer's research is providing momentum for clinical trials of "cocktail" treatments targeting the two hallmark proteins associated with the mind-robbing disease, according to interviews with researchers and pharmaceutical executives. Drugmakers Eisai and Biogen reported in September that their therapy lecanemab could slow progress of the disease by 27% over 18 months compared with a placebo. The finding validates the theory that clearing the amyloid protein that forms clumps in the brains of Alzheimer's patients could slow or halt the disease and has strengthened the support from some scientists for simultaneously targeting another notorious protein linked to Alzheimer's: tau. Eisai and Biogen are scheduled to present full data from their lecanemab study on Tuesday at the Clinical Trials on Alzheimer's Disease conference in San Francisco. The U.S. Food and Drug Administration is expected to make a decision by early January on the companies' application for accelerated approval. If approved on an accelerated basis, the companies said they would immediately apply for full U.S. regulatory approval which could help secure Medicare coverage.

The National Pharmacy Association (NPA)'s Health Education Foundation (HEF) has funded a major study that aimed to test the SPUR tool and evaluate how effective it was at measuring medicines adherence. The study has been published in the British Medical Journal Open. Dr Joshua Wells, a fourth year PhD candidate at Kingston University, who was awarded the NPA bursary, was the lead researcher for the SPUR UK study, under the guidance of Professor Reem Kayyali. Created by Observia, a health research group, SPUR is a self-assessment questionnaire which helps to detect a patient's risk of medicine non-adherence and aims to accurately articulate the reasons for health behaviour. As well as funding from HEF, the study was made possible via a partnership with Kingston University and Kingston Hospital. HEF chair of Trustees, Dr Ian Cubbin, said: "We are delighted that NPA's Health Education Foundation has played a part in such an important study. This research could lead ultimately to a far more personalised, tailored approach to medicines optimisation - recognising that people's medicines behaviour can be highly individual to them."

Researchers at at an Australian university have developed a new form of antibiotic that can be swiftly re-engineered to avoid resistance to dangerous superbugs. The antibiotic, which was developed by PhD candidate Priscila Cardoso and major supervisor Dr Celine Valery from RMIT's School of Health and Biosciences, has a basic architecture that allows it to be generated quickly and cheaply in a lab. The antibiotic, Priscilicidin, has tiny amino acid building blocks that allow it to be tailored to combat various types of antimicrobial resistance. With the World Health Organization calling antimicrobial resistance "one of the top ten global public health threats facing humanity", developing new antibiotics has become more urgent than ever. Professor Charlotte Conn, one of Cardoso's PhD supervisors, said given that urgency, Priscilicidin was an exciting breakthrough for public health. Priscilicidin is a type of antimicrobial peptide. These peptides are produced by all living organisms as the first defence against bacteria and viruses.

Pharma giant, Pfizer has announced plans to cut 500 jobs at its Sandwich site in Kent, England as part of its ongoing $3.5 billion cost-cutting drive. The company is also planning to shut its Pharmaceutical Sciences Small Molecule (PSSM) capabilities at the site, a spokesperson of the company told FiercePharma. However, the Sandwich site will remain open and other functions will continue with "a different size," the spokesperson added. Currently, around 940 people are employed at the site, which is the location where Pfizer scientists first discovered Viagra. "We are proud of our heritage of breakthrough science in the UK and we will retain a scientific presence in the U.K. including at our Discovery Park location in Sandwich," Pfizer's spokesperson confirmed in an email to FiercePharma.

British scientists said on Thursday (December 30) they would be studying whether higher doses of a cheap and widely used steroid called dexamethasone could work better for patients with severe Covid-19 compared to the standard low doses. Last year, the same scientists conducting the large trial, dubbed RECOVERY, showed that dexamethasone was able to save the lives of Covid-19 patients in what was called a "major breakthrough" in the coronavirus pandemic. They had found that a 6 mg daily dose of dexamethasone, which is used to reduce inflammation in diseases such as arthritis, cut death rates by around a third among the most severely ill Covid-19 patients in hospitals. "Given how quickly the Omicron variant is spreading, we can expect to see patients admitted to hospital with severe Covid-19 for a while to come," said Peter Horby, an Oxford University professor co-leading the trial.

The Association of the British Pharmaceutical Industry (ABPI) has welcomed the new research guidance published by NHS England for the integrated care systems. The guidance is said to reflect the benefits of delivering research, for patients, staff and healthcare system performance, including the economic benefits for the NHS. Jennifer Harris, ABPI's Director of Research Policy, said: "This guidance is clear on what good research practice looks like and it's great to see it out and available for the NHS to use. "A research-active NHS delivers huge value to patients, staff and the system itself. We hope that putting this guidance into action will help Integrated Care Systems realise the huge benefits that research can offer, and help make the UK once again a destination of choice for developing the medical breakthroughs people need."

An old proverb that comes to mind in the pursuit of the twin objectives of serenity and health is this: the mind and the body are inexorably intertwined. This essential, often overlooked, connection is at the heart of our ability to manage stress and foster a sense of well-being. But how does one truly achieve relaxation, and how does it translate to a healthier way of living? From ancient practices to modern breakthroughs, the path to stress relief and overall health is illuminated by a multifaceted approach that combines mindfulness, diet, exercise, and even the judicious use of calming products. The nexus between stress relief and well-being is rich and layered. By exploring various strategies, we can uncover the tapestry of tranquility that ultimately leads to a richer, more vital life. Relaxation Leads to a Healthier Mind and Body Relaxation is not just a warm bath or an hour of Netflix; it is the conscious unclenching of the mind and the body's release of tension. It's a critical ingredient in the complex recipe for overall health and plays a significant role in the functioning of the immune system, the maintenance of a healthy heart, and the regulation of moods. To relax, people take wellness CBD gummies that offer a natural, convenient route to unwind without the psychedelic effects often associated with the substance. Relaxation techniques also encompass meditation, deep breathing, progressive muscle relaxation, and guided imagery. Each method has its loyal practitioners, but the central tenet remains the same - in relaxation lies a wellspring of health.

In an announcement following Keir Starmer's and Wes Streeting's visit to a hospital in the East Midlands, Labour Party has unveiled a groundbreaking partnership with Virgin Media O2 aimed at ensuring every child with type 1 diabetes can access the latest medical technology to better manage diabetes. With the NHS providing patients with type 1 diabetes the option of an 'artificial pancreas' in the next five years to manage insulin levels and Continuous Glucose Monitors launched nearly 2 years ago to monitor children's glucose levels, the initiative aims to address the financial barrier hindering hundreds of families from benefiting from this breakthrough. Labour's plan to provide every child in need a smartphone, facilitating access to modern glucose monitors, aligns with the centre-leftist party's broader vision to harness technology for healthcare transformation. Announcing the partnership in an interview with ITV News, Keir Starmer, Labour Party Leader, highlighted the lack of equitable access to medical advancement amongst patients as "travesty" and "impact of fourteen years of Conservative chaos has had on the NHS", stating:

A new research claims that teenage girls who eat high amounts of saturated fats tend to develop denser breasts 15 years later. This is a breakthrough because greater breast density is a risk factor for breast cancer. Adolescent years are a critical time for breast development in girls.